Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H30O2 |
Molecular Weight | 254.4082 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCC\C=C\CCCCCCCC(O)=O
InChI
InChIKey=SECPZKHBENQXJG-BQYQJAHWSA-N
InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h7-8H,2-6,9-15H2,1H3,(H,17,18)/b8-7+
Molecular Formula | C16H30O2 |
Molecular Weight | 254.4082 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Palmitoleic acid, commonly known as omega-7, is a rare monounsatured fatty acid, which was generally reported to benefit the skin in promoting epithelialisation, and certain gynaecological problems (vaginal mycoses). Until now, sea buckthorn (Hippophae rhamnoides), a shrub widely found in Europe and Asia, and macadamia nuts have been the principal sources. Palmitoleic acid (PMA) has anti-inflammatory and antidiabetic activities. Palmitoleic acid is a gap junction uncoupler.
Originator
Curator's Comment: Palmitoleic acid (16 carbon atoms) was noticed first in 1854 by Hofstädter P.G. in sperm whale oil and named physetoleic acid. In 1906 Bull H. discovered its molecular composition, at the time when Lewkowitsch gave the present name. The structure was established in 1925 by Armstrong E.F. et al.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map04540 |
|||
Target ID: CHEMBL5346 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20484837 |
|||
Target ID: CHEMBL1075142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20484837 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Palmitoleic Acid Approved UseA purified form of omega-7 to help combat type II diabetes, atherosclerosis and metabolic syndrome. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28185444
A double-blind, randomized, placebo-controlled pilot study was conducted in 20 patients with UC. A dose of 720 mg/day of Cis-palmitoleic acid was orally administered during 8 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12163339
Endothelium-dependent responses were assessed in myometrial small arteries isolated from pregnant women, using pressure myography. Responses to bradykinin were attenuated in the presence of palmitoleic acid (50 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:03:19 GMT 2023
by
admin
on
Sat Dec 16 09:03:19 GMT 2023
|
Record UNII |
65DJ825A3Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
59265
Created by
admin on Sat Dec 16 09:03:19 GMT 2023 , Edited by admin on Sat Dec 16 09:03:19 GMT 2023
|
PRIMARY | |||
|
10030-73-6
Created by
admin on Sat Dec 16 09:03:19 GMT 2023 , Edited by admin on Sat Dec 16 09:03:19 GMT 2023
|
PRIMARY | |||
|
DTXSID7021603
Created by
admin on Sat Dec 16 09:03:19 GMT 2023 , Edited by admin on Sat Dec 16 09:03:19 GMT 2023
|
PRIMARY | |||
|
5282745
Created by
admin on Sat Dec 16 09:03:19 GMT 2023 , Edited by admin on Sat Dec 16 09:03:19 GMT 2023
|
PRIMARY | |||
|
65DJ825A3Z
Created by
admin on Sat Dec 16 09:03:19 GMT 2023 , Edited by admin on Sat Dec 16 09:03:19 GMT 2023
|
PRIMARY |